FOUNDERS

David H. Thompson

Founder & CEO

Jewell was founded in 2012 by David H. Thompson, PhD. Dr. Thompson is an author of 7 patents/applications and over 125 peer-reviewed publications; has founded four technology-based start-up companies and been awarded $14M in funding.

PROFILE

Jewell Laboratories is commercializing intellectual property developed at Purdue University in the lab of Dr. David H. Thompson. The company’s first product will be an effective treatment for Niemann-Pick Type C (NPC). Jewell has developed a family of long-circulating cyclodextrin polymers which act as mobilizing agents to induce natural elimination of cholesterol from the body. Animal studies have shown extension of lifespan by 40% and restoration of normal metabolic activity in patient-derived NPC cells by rebalancing cholesterol levels. Additionally, the therapeutic effects can be maintained at a reduced dose and treatment frequency, when compared to competitive alternatives, with a reduction in disease burden in liver, spleen, lung, and other organs that NPC affects.

FUNDING PHASE
RAISED TO-DATE
READY TO TALK?


Entrepreneur
Investor
Mentor
Talent
Location:
Foundry
WestGate